In summary, systemic administration of the oncolytic Ad, replicating under the control of tumor microenvironment- and HCC-targeting AFP promoter, can induce a potent inhibition of tumor growth, with a good safety profile, rendering it a promising candidate for the treatment of primary tumors and distant metastases in patients with late stages of cancer. This evidence concerns the gene AFP and hepatocellular carcinoma.